STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 89 filers reported holding STOKE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.22 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $33 | -79.0% | 8,440 | -43.1% | 0.00% | – |
Q2 2023 | $157 | -17.4% | 14,829 | -35.1% | 0.00% | – |
Q1 2023 | $190 | +11.8% | 22,860 | +23.9% | 0.00% | – |
Q4 2022 | $170 | -99.9% | 18,443 | +74.6% | 0.00% | – |
Q3 2022 | $135,000 | +3.1% | 10,563 | +6.5% | 0.00% | – |
Q2 2022 | $131,000 | +33.7% | 9,921 | +111.8% | 0.00% | – |
Q1 2022 | $98,000 | -91.2% | 4,685 | -89.9% | 0.00% | – |
Q4 2021 | $1,112,000 | +377.3% | 46,338 | +405.4% | 0.00% | – |
Q3 2021 | $233,000 | -37.0% | 9,169 | -16.7% | 0.00% | – |
Q2 2021 | $370,000 | -46.1% | 11,013 | -37.6% | 0.00% | – |
Q1 2021 | $686,000 | +115.7% | 17,647 | +243.8% | 0.00% | – |
Q4 2020 | $318,000 | +38.9% | 5,133 | -24.7% | 0.00% | – |
Q3 2020 | $229,000 | -4.2% | 6,815 | -31.7% | 0.00% | – |
Q2 2020 | $239,000 | +68.3% | 9,981 | +61.0% | 0.00% | – |
Q1 2020 | $142,000 | -48.9% | 6,198 | -37.0% | 0.00% | – |
Q4 2019 | $278,000 | +115.5% | 9,836 | +63.9% | 0.00% | – |
Q3 2019 | $129,000 | +377.8% | 6,001 | +556.6% | 0.00% | – |
Q2 2019 | $27,000 | – | 914 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 16,786,713 | $562,187,000 | 75.80% |
RTW INVESTMENTS, LP | 3,544,248 | $118,697,000 | 2.86% |
Cormorant Asset Management, LP | 1,537,807 | $51,501,000 | 1.98% |
Redmile Group, LLC | 2,549,506 | $85,383,000 | 1.57% |
Birchview Capital, LP | 40,000 | $1,340,000 | 0.45% |
HighVista Strategies LLC | 17,082 | $572,000 | 0.42% |
Perceptive Advisors | 671,978 | $22,505,000 | 0.33% |
GILDER GAGNON HOWE & CO LLC | 1,490,153 | $49,905,000 | 0.31% |
Artal Group S.A. | 270,750 | $9,067,000 | 0.22% |
VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 323 | $11,000 | 0.20% |